These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30904164)

  • 1. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma.
    Nakagawa N; Kikuchi K; Yagyu S; Miyachi M; Iehara T; Tajiri T; Sakai T; Hosoi H
    Biochem Biophys Res Commun; 2019 May; 512(3):524-530. PubMed ID: 30904164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
    Wada M; Horinaka M; Yamazaki T; Katoh N; Sakai T
    PLoS One; 2014; 9(11):e113217. PubMed ID: 25422890
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Dolgikh N; Hugle M; Vogler M; Fulda S
    Cancer Res; 2018 Apr; 78(8):2000-2013. PubMed ID: 29437705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
    Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
    Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy.
    Tanaka T; Higashi M; Kimura K; Wakao J; Fumino S; Iehara T; Hosoi H; Sakai T; Tajiri T
    J Pediatr Surg; 2016 Dec; 51(12):2074-2079. PubMed ID: 27686482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
    Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
    Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma.
    Martinelli S; McDowell HP; Vigne SD; Kokai G; Uccini S; Tartaglia M; Dominici C
    Genes Chromosomes Cancer; 2009 Nov; 48(11):975-82. PubMed ID: 19681119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by RAS/RAF mutations.
    Agaram NP; Huang SC; Tap WD; Wexler LH; Antonescu CR
    Genes Chromosomes Cancer; 2022 Mar; 61(3):131-137. PubMed ID: 34755412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
    Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma.
    Hensch NR; Bondra K; Wang L; Sreenivas P; Zhao XR; Modi P; Vaseva AV; Houghton PJ; Ignatius MS
    Mol Cancer Ther; 2023 Jan; 22(1):123-134. PubMed ID: 36162055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
    Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
    Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.
    Stewart E; McEvoy J; Wang H; Chen X; Honnell V; Ocarz M; Gordon B; Dapper J; Blankenship K; Yang Y; Li Y; Shaw TI; Cho JH; Wang X; Xu B; Gupta P; Fan Y; Liu Y; Rusch M; Griffiths L; Jeon J; Freeman BB; Clay MR; Pappo A; Easton J; Shurtleff S; Shelat A; Zhou X; Boggs K; Mulder H; Yergeau D; Bahrami A; Mardis ER; Wilson RK; Zhang J; Peng J; Downing JR; Dyer MA;
    Cancer Cell; 2018 Sep; 34(3):411-426.e19. PubMed ID: 30146332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hedgehog signal inhibitor forskolin suppresses cell proliferation and tumor growth of human rhabdomyosarcoma xenograft.
    Yamanaka H; Oue T; Uehara S; Fukuzawa M
    J Pediatr Surg; 2011 Feb; 46(2):320-5. PubMed ID: 21292081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma.
    Li S; Fu J; Yang J; Ma H; Bhutani D; Mapara MY; Marcireau C; Lentzsch S
    Blood; 2021 Apr; 137(13):1754-1764. PubMed ID: 33036022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.
    Schaaf G; Hamdi M; Zwijnenburg D; Lakeman A; Geerts D; Versteeg R; Kool M
    Cancer Res; 2010 Jan; 70(2):762-71. PubMed ID: 20068162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.
    Okumura S; Jänne PA
    Clin Cancer Res; 2014 Aug; 20(16):4193-9. PubMed ID: 24907112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.
    Teot LA; Schneider M; Thorner AR; Tian J; Chi YY; Ducar M; Lin L; Wlodarski M; Grier HE; Fletcher CDM; van Hummelen P; Skapek SX; Hawkins DS; Wagers AJ; Rodriguez-Galindo C; Hettmer S
    Cancer; 2018 May; 124(9):1973-1981. PubMed ID: 29461635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.